VolitionRx Announces Submission of Manuscript for Nu.Q® Vet Cancer Test in Cats
Rhea-AI Summary
Volition (NYSE AMERICAN: VNRX) submitted a peer‑review manuscript reporting the Nu.Q® Vet Feline prototype assay detected 86% of feline lymphomas at 97% specificity.
The company says publication is expected to trigger a $5 million contractual milestone and aims to commercialize a blood-based feline cancer screening test via labs and point-of-care channels.
Positive
- Assay sensitivity detecting 86% of feline lymphomas
- Assay specificity measured at 97%
- $5 million contractual milestone tied to publication
- Nu.Q® Vet canine test available in 20+ countries
- 73.8 million pet cats in the U.S. (addressable population)
Negative
- Manuscript is submitted and not yet peer reviewed
- Milestone payment is contingent on subsequent publication
- Nu.Q® Vet Feline test remains in product development
News Market Reaction – VNRX
In the May 6 session, VNRX gained 6.87%, reflecting a notable positive market reaction. Argus tracked a peak move of +13.0% during that session. Argus tracked a trough of -4.9% from its starting point during tracking. Our momentum scanner triggered 10 alerts that day, indicating notable trading interest and price volatility.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Apr 29 | Sepsis test progress | Positive | -5.0% | Reported successful nucleosome detection via finger-prick lateral flow prototype in sepsis. |
| Apr 23 | Listing compliance plan | Positive | -8.7% | NYSE American accepted plan giving time until Aug 6, 2027 to regain compliance. |
| Apr 20 | Product launch | Positive | -8.7% | Launched rNuQ™ webshop to commercialize recombinant nucleosomes and broaden Nu.Q® Discover. |
| Mar 31 | Full-year earnings | Positive | -1.0% | Reported 2025 revenue growth, lower operating expenses, reduced net loss and cash burn. |
| Mar 31 | Non-dilutive funding | Positive | +6.3% | Secured €2.0M non-dilutive Belgian funding to support Nu.Q® portfolio development. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent Volition announcements with seemingly positive operational or funding developments have often been followed by negative 24-hour price reactions, with only one clear alignment between upbeat funding news and a positive move.
Over the past months, Volition reported several developments: sepsis-related nucleosome detection in ICU patients (Apr 29, 2026), NYSE American compliance plan acceptance (Apr 23, 2026), launch of the rNuQ™ webshop (Apr 20, 2026), full-year 2025 results with $1.7M revenue and reduced losses (Mar 31, 2026), and €2.0 million in non-dilutive Belgian funding (Mar 31, 2026). Despite mostly constructive news flow, four of these five releases saw negative 24-hour price reactions, highlighting a pattern of market skepticism toward updates.
Key Terms
liquid biopsy medical
lymphoma medical
nucleosomes medical
biomarker medical
compound annual growth rate financial
AI-generated analysis. How Rhea-AI works. Not financial advice.
The publication of this study in a peer reviewed journal is expected subsequently to unlock a
Dr Annalisa Canale, Volition and first author on the paper commented:
"Feline oncology lacks tumor biomarkers and so cancer in cats have been notoriously difficult to diagnose early.
"Building on our prior findings for canine lymphoma3-5, this study aimed to highlight the utility of circulating nucleosomes as biomarker to differentiate healthy vs intermediate-large cell lymphoma in cats.
"Nucleosome levels were significantly higher in cats with intermediate-large cell lymphoma compared to healthy controls indicating the potential role of H3.1-nucleosomes as a new useful biomarker for screening intermediate-large cell lymphoma in cats."
Gael Forterre, Chief Commercial Officer, Volition commented:
"This represents a tremendous commercial opportunity for Volition:
- the publication of this study in a peer reviewed journal is expected subsequently to unlock a
$5 million - we plan to generate ongoing revenue in this large and growing market where our technology meets an unmet need.
"Our mission is to make cancer screening a routine part of every pet's annual wellness check and following the successful international rollout of our canine cancer test, we have now demonstrated that our technology is also effective for cats.
"We look forward to completing product development and making the Nu.Q® Vet Feline Test available through our distribution networks including reference laboratories and point-of-care platforms.
"The Nu.Q® Vet Canine test is already available in more than 20 countries, and we believe the addition of a feline equivalent could potentially double our total addressable market in the companion animal space."
The Nu.Q® Vet Feline Test taps into a significant, rapidly growing market:
- Large Population: There are approximately 73.8 million pet cats in
the United States alone6. - High Risk: It is estimated that approximately 1 in 5 cats will develop cancer in their lifetime7. Feline lymphoma, the most common cancer in the species, is a primary target for the Nu.Q® assay.
- The "Senior" Segment: Over
25% ofU.S. cats are considered seniors (aged 8+)8, representing a recurring annual screening opportunity for over 18 million pets in theU.S. 6,8 - Market Growth: The North American veterinary oncology market is projected to reach
$1.77 billion
The paper should be available on a preprint service in the coming days.
- Data on File
- Vail D, Thamm D, Liptak J, eds. Withrow and MacEwen's Small Animal Clinical Oncology. 6th ed. Elsevier Health Sciences; 2019.
- H. M. Wilson‑Robles et al, BMC Vet Res, 2022, https://doi.org/10.1186/s12917-022-03429-8
- C. Dolan et al, BMC Vet Res, 2021 https://doi.org/10.1186/s12917-021-02991-x
- H. M. Wilson‑Robles et al, BMC Vet Res, 2021, https://doi.org/10.1186/s12917-021-02934-6
- AVMA Pet Ownership Sourcebook (2025) & APPA National Pet Owners Survey (2025)
- Can Cats Get Cancer? Understanding Feline Cancers Like Lymphoma & SCC. Imprimed
- Data on file, Volition TAM model
- Towards Healthcare: Veterinary Oncology Market Insights (October 2025)
About Volition
About Volition: Volition is a multi-national company focused on advancing the science of epigenetics. Volition is dedicated to saving lives and improving outcomes for people and animals with life-altering diseases through earlier detection, as well as disease and treatment monitoring.
Through its subsidiaries, Volition is developing and commercializing simple, easy to use, cost-effective blood tests to help detect and monitor a range of diseases, including some cancers and diseases associated with NETosis, such as sepsis. Early detection and monitoring have the potential not only to prolong the life of patients, but also to improve their quality of life.
Volition's research and development activities are centered in
The contents found at Volition's website address are not incorporated by reference into this document and should not be considered part of this document. Such website address is included in this document as an inactive textual reference only.
Media Enquiries: Louise Batchelor, Volition, mediarelations@volition.com, +44 (0)7557 774620
Safe Harbor Statement
Statements in this press release or associated video or link may be "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, that concern matters that involve risks and uncertainties that could cause actual results to differ materially from those anticipated or projected in the forward-looking statements. Words such as "expects," "anticipates," "intends," "plans," "aims," "targets," "believes," "seeks," "estimates," "optimizing," "potential," "goal," "suggests," "could," "would," "should," "may," "will" and similar expressions identify forward-looking statements. These forward-looking statements relate to, among other topics, Volition's expectations related to revenue opportunities, milestone payments and growth, the effectiveness and availability of Volition's blood-based diagnostic, prognostic and disease monitoring tests, Volition's ability to develop and successfully commercialize such test platforms for early detection of cancer and other diseases as well as serving as a diagnostic, prognostic or disease monitoring tools for such diseases, Volition's expectations regarding future publications, Volition's success in securing licensing and/or distribution agreements with third parties for its products, and Volition's expectations regarding the terms of such agreements. Volition's actual results may differ materially from those indicated in these forward-looking statements due to numerous risks and uncertainties, including, without limitation, results of studies testing the efficacy of its tests. For instance, if Volition fails to develop and commercialize diagnostic, prognostic or disease monitoring products, it may be unable to execute its plan of operations. Other risks and uncertainties include Volition's failure to obtain necessary regulatory clearances or approvals to distribute and market future products; a failure by the marketplace to accept the products in Volition's development pipeline or any other diagnostic, prognostic or disease monitoring products Volition might develop; Volition's failure to secure adequate intellectual property protection; Volition will face fierce competition and Volition's intended products may become obsolete due to the highly competitive nature of the diagnostics and disease monitoring market and its rapid technological change; downturns in domestic and foreign economies; and other risks, including those identified in Volition's most recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q, as well as other documents that Volition files with the Securities and Exchange Commission. These statements are based on current expectations, estimates and projections about Volition's business based, in part, on assumptions made by management. These statements are not guarantees of future performance and involve risks, uncertainties and assumptions that are difficult to predict. Forward-looking statements are made as of the date of this release, and, except as required by law, Volition does not undertake an obligation to update its forward-looking statements to reflect future events or circumstances.
rNuQ™, Nucleosomics™, Capture-PCR™, Capture-Seq™ and Nu.Q® and their respective logos are trademarks and/or service marks of VolitionRx Limited and its subsidiaries. All other trademarks, service marks and trade names referred to in this press release or associated video or link are the property of their respective owners. Additionally, unless otherwise specified, all references to "$" refer to the legal currency of
Image - https://mma.prnewswire.com/media/2973726/VolitionRx_Limited.jpg
View original content to download multimedia:https://www.prnewswire.com/news-releases/volitionrx-announces-submission-of-manuscript-for-nuq-vet-cancer-test-in-cats-302764020.html
SOURCE VolitionRx Limited